Data-Driven Antimicrobial Stewardship in Tertiary Hospitals

Designing a rigorous MBA project around data-driven antimicrobial stewardship can showcase analytical depth and healthcare impact. This report outlines how to implement and evaluate data-driven antimicrobial stewardship in tertiary hospitals using KPIs, EHR analytics, and cost–benefit methods suitable for academic assessment and real-world pilots.

Why Antimicrobial Stewardship Needs a Data-First Strategy

Escalating antimicrobial resistance strains budgets, lengthens stays, and worsens outcomes. A data-first approach links prescribing behaviors to outcomes, enabling targeted interventions. This project demonstrates how to quantify utilization, adherence, and resistance patterns while aligning with hospital governance and infection control committees.

Project Aim and Measurable Outcomes

The primary aim is to design, implement, and evaluate a hospital-wide stewardship model that reduces broad-spectrum antibiotic use without harming patient outcomes. Secondary outcomes include reduced Clostridioides difficile rates, shorter average length of stay, and lower pharmacy spend per discharge.

Scope, Modules, and Stakeholder Interfaces

The scope spans adult inpatient wards, ICU, and emergency admissions requiring IV antibiotics. Key modules include baseline analytics, intervention design, decision support, education, and KPI dashboards. Stakeholders are ID physicians, pharmacists, nursing leaders, quality teams, microbiology, and IT.

Module 1: Baseline Utilization and Resistance Mapping

Extract 12 months of prescribing data by ATC code, route, dose, and duration. Compute DDD per 100 bed-days and days of therapy per 1,000 patient-days. Map antibiograms by unit and organism to identify hotspots of resistance and inappropriate empiric choices.

Module 2: Guideline and Formulary Alignment

Compare hospital protocols to national guidelines. Flag misalignments in empiric therapy, de-escalation, and duration. Propose a tiered formulary with preauthorization for high-risk agents and auto-stop policies for targeted antibiotics at 72 hours.

Module 3: EHR-Embedded Clinical Decision Support

Design CDS nudges for weight-based dosing, renal adjustments, and duplicate therapy alerts. Add order-set defaults for indication capture and mandatory review at 48–72 hours. Include antibiogram-linked suggestions by ward and infection source.

Module 4: Prospective Audit and Feedback Workflows

Define daily pharmacist-ID rounds for high-cost or broad-spectrum orders. Create a recommendation log capturing acceptance rates, reasons for override, and turnaround time to action. Close the loop with attending physicians via concise notes in the EHR.

Module 5: Education and Behavior Change

Run microlearning sessions on de-escalation and duration. Share unit-level scorecards highlighting peer comparisons. Recognize high-adherence teams publicly, reinforcing norms.

Methodology and Data Architecture

Use a pre–post quasi-experimental design with interrupted time series. Extract data from pharmacy, EHR orders, microbiology, and ADT. A star schema can host fact tables for orders and cultures with dimensions for patient, unit, prescriber, and time. Validate data completeness and outliers before analysis.

Primary KPIs and Operational Definitions

• DDD per 100 bed-days (overall and by class)
• Days of therapy per 1,000 patient-days
• Proportion of guideline-concordant empiric therapy
• Time to de-escalation within 72 hours
• C. difficile infection rate per 10,000 patient-days
• Acceptance rate of stewardship recommendations
• Pharmacy cost per discharge (risk-adjusted)

Risk Adjustment and Statistical Plan

Adjust outcomes for case mix (CCI), ICU stay, and device use. Apply segmented regression for trend changes. Use SPC charts for DDD and DOT. Report confidence intervals and sensitivity analyses excluding pandemic-period anomalies.

Cost–Benefit and Budget Impact Assessment

Estimate direct savings from reduced broad-spectrum use and avoided days of therapy. Quantify indirect benefits from shorter length of stay and fewer C. difficile cases. Include incremental costs for stewardship FTEs, CDS build, and training. Present net present value and one-way sensitivity analyses on acceptance rates and drug prices.

Implementation Roadmap and Governance

Establish a steering group chaired by ID and Pharmacy. Phase 1: data pipeline and dashboards. Phase 2: pilot in ICU and respiratory wards. Phase 3: scale to hospital-wide adoption. Review KPIs monthly with corrective actions for underperforming units.

Sample Timeline and Milestones

• Weeks 1–4: data extraction, KPI definitions, and baselines
• Weeks 5–8: CDS build and user testing
• Weeks 9–16: pilot with daily audit and feedback
• Weeks 17–24: hospital rollout, education, and scorecards

Learning Outcomes for MBA Candidates

Students will master KPI design, quasi-experimental evaluation, and change management. They will gain hands-on experience with EHR analytics in hospitals, formulary policy, and economic modeling, preparing them to lead stewardship or quality improvement portfolios.

Documentation and Deliverables

Produce a methods protocol, data dictionary, dashboard mock-ups, CDS logic catalog, and a final report with statistical outputs and a sustainability plan. Append de-identified case vignettes illustrating de-escalation decisions.

Ethics, Safety, and Compliance Considerations

Ensure IRB or ethics exemption for QI, data de-identification, and audit trails for CDS overrides. Align with antimicrobial policy committees and pharmacovigilance processes to track adverse events and ensure patient safety.

Frequently Asked Questions

How does data-driven antimicrobial stewardship differ from traditional programs?

It embeds analytics and CDS into daily workflows, enabling real-time nudges, KPI tracking, and rapid cycle improvements rather than retrospective audits alone.

Which units should be prioritized first?

Start with ICU, oncology, and high-resistance wards where broad-spectrum use is concentrated and measurable gains are most likely.

What minimum data is needed to start?

Antibiotic orders with dose, duration, indication, patient-days, unit identifiers, and microbiology sensitivity results for top organisms are sufficient for initial KPIs.

How do we prevent alert fatigue?

Limit alerts to high-severity scenarios, use tiered thresholds, and monitor override rates, iterating message clarity and timing.

Key Heading: Data-Driven Antimicrobial Stewardship in Practice

This section reinforces the centrality of data-driven antimicrobial stewardship by tying KPIs, CDS, and audit workflows into a continuous improvement loop sustained by governance and education.

Further Reading and Related Resources

For a broader list of healthcare project ideas, see the MBA Hospital/Healthcare Topic List. Explore category-specific guides in MBA Hospital/Healthcare Reports for complementary methodologies.

Evidence and Technical Reference

Consult the WHO AWaRe antibiotic classification and stewardship guidance for policy alignment: WHO stewardship resources.

Short CTA to Discuss Your Proposal

Need feedback on your stewardship study design or KPIs? Reach out via Contact EmptyDoc to refine your academic proposal and pilot plan.

Conclusion: Embedding Data-Driven Antimicrobial Stewardship

By centering data-driven antimicrobial stewardship within EHR workflows, dashboards, and governance, hospitals can curb resistance, cut costs, and improve outcomes. This MBA-ready project blueprint offers measurable KPIs, practical modules, and a feasible rollout for credible academic and operational impact.